Loading…
Clinical pharmacokinetics of nitrates
The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and i...
Saved in:
Published in: | Cardiovascular drugs and therapy 1994-10, Vol.8 (5), p.693-699 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3 |
container_end_page | 699 |
container_issue | 5 |
container_start_page | 693 |
container_title | Cardiovascular drugs and therapy |
container_volume | 8 |
creator | BOGAERT, M. G |
description | The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied. |
doi_str_mv | 10.1007/bf00877116 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77765742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77765742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3</originalsourceid><addsrcrecordid>eNo9kDtPwzAURi0EKqWwsCNlAAakwPUjvs4IFQWkSiwwR7ZrC0Ne2OnAvyeoodM3nKNvOIScU7ilAHhnPIBCpFQekDktkOfIBD0kcygZ5JyBPCYnKX3CKJelmpEZKuRCyjm5WtahDVbXWf-hY6Nt9xVaNwSbss5nbRiiHlw6JUde18mdTbsg76vHt-Vzvn59elner3PLBQz5RvNNAUpSK71Az5EaW0jllVFWlsZyVhjUTksA7YXxwjMKohgZdYxRwxfkevfbx-5769JQNSFZV9e6dd02VYgoCxRsFG92oo1dStH5qo-h0fGnolD9NakeVv9NRvliet2axm326hRh5JcT12ks4aNubUh7jXMExgX_BWBwZxc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77765742</pqid></control><display><type>article</type><title>Clinical pharmacokinetics of nitrates</title><source>Springer Nature - Connect here FIRST to enable access</source><creator>BOGAERT, M. G</creator><creatorcontrib>BOGAERT, M. G</creatorcontrib><description>The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/bf00877116</identifier><identifier>PMID: 7873466</identifier><identifier>CODEN: CDTHET</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Angina Pectoris - drug therapy ; Antianginal agents. Coronary vasodilator agents ; Biological and medical sciences ; Cardiovascular system ; Delayed-Action Preparations ; Drug Administration Routes ; Half-Life ; Humans ; Isosorbide Dinitrate - administration & dosage ; Isosorbide Dinitrate - analogs & derivatives ; Isosorbide Dinitrate - blood ; Isosorbide Dinitrate - pharmacokinetics ; Isosorbide Dinitrate - therapeutic use ; Liver - metabolism ; Medical sciences ; Nitrates - administration & dosage ; Nitrates - blood ; Nitrates - pharmacokinetics ; Nitrates - therapeutic use ; Nitroglycerin - blood ; Nitroglycerin - pharmacokinetics ; Pharmacology. Drug treatments ; Structure-Activity Relationship ; Vasodilation - drug effects ; Vasodilator Agents - blood ; Vasodilator Agents - pharmacokinetics ; Vasodilator Agents - therapeutic use</subject><ispartof>Cardiovascular drugs and therapy, 1994-10, Vol.8 (5), p.693-699</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3</citedby><cites>FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3370234$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7873466$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BOGAERT, M. G</creatorcontrib><title>Clinical pharmacokinetics of nitrates</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><description>The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.</description><subject>Angina Pectoris - drug therapy</subject><subject>Antianginal agents. Coronary vasodilator agents</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Delayed-Action Preparations</subject><subject>Drug Administration Routes</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Isosorbide Dinitrate - administration & dosage</subject><subject>Isosorbide Dinitrate - analogs & derivatives</subject><subject>Isosorbide Dinitrate - blood</subject><subject>Isosorbide Dinitrate - pharmacokinetics</subject><subject>Isosorbide Dinitrate - therapeutic use</subject><subject>Liver - metabolism</subject><subject>Medical sciences</subject><subject>Nitrates - administration & dosage</subject><subject>Nitrates - blood</subject><subject>Nitrates - pharmacokinetics</subject><subject>Nitrates - therapeutic use</subject><subject>Nitroglycerin - blood</subject><subject>Nitroglycerin - pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Structure-Activity Relationship</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - blood</subject><subject>Vasodilator Agents - pharmacokinetics</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><recordid>eNo9kDtPwzAURi0EKqWwsCNlAAakwPUjvs4IFQWkSiwwR7ZrC0Ne2OnAvyeoodM3nKNvOIScU7ilAHhnPIBCpFQekDktkOfIBD0kcygZ5JyBPCYnKX3CKJelmpEZKuRCyjm5WtahDVbXWf-hY6Nt9xVaNwSbss5nbRiiHlw6JUde18mdTbsg76vHt-Vzvn59elner3PLBQz5RvNNAUpSK71Az5EaW0jllVFWlsZyVhjUTksA7YXxwjMKohgZdYxRwxfkevfbx-5769JQNSFZV9e6dd02VYgoCxRsFG92oo1dStH5qo-h0fGnolD9NakeVv9NRvliet2axm326hRh5JcT12ks4aNubUh7jXMExgX_BWBwZxc</recordid><startdate>19941001</startdate><enddate>19941001</enddate><creator>BOGAERT, M. G</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19941001</creationdate><title>Clinical pharmacokinetics of nitrates</title><author>BOGAERT, M. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Angina Pectoris - drug therapy</topic><topic>Antianginal agents. Coronary vasodilator agents</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Delayed-Action Preparations</topic><topic>Drug Administration Routes</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Isosorbide Dinitrate - administration & dosage</topic><topic>Isosorbide Dinitrate - analogs & derivatives</topic><topic>Isosorbide Dinitrate - blood</topic><topic>Isosorbide Dinitrate - pharmacokinetics</topic><topic>Isosorbide Dinitrate - therapeutic use</topic><topic>Liver - metabolism</topic><topic>Medical sciences</topic><topic>Nitrates - administration & dosage</topic><topic>Nitrates - blood</topic><topic>Nitrates - pharmacokinetics</topic><topic>Nitrates - therapeutic use</topic><topic>Nitroglycerin - blood</topic><topic>Nitroglycerin - pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Structure-Activity Relationship</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - blood</topic><topic>Vasodilator Agents - pharmacokinetics</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BOGAERT, M. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BOGAERT, M. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical pharmacokinetics of nitrates</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>1994-10-01</date><risdate>1994</risdate><volume>8</volume><issue>5</issue><spage>693</spage><epage>699</epage><pages>693-699</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><coden>CDTHET</coden><abstract>The pharmacokinetics of organic nitrates are discussed with emphasis on the possible clinical relevance. For glyceryl trinitrate, the measurement of plasma concentrations is very difficult. Its pharmacokinetics are unusual, with a very rapid disappearance from plasma, and large intraindividual and interindividual variations. After oral administration, there seems to be a very extensive first-pass hepatic extraction and the plasma concentrations are often below the detection limit; after sublingual administration, glyceryl trinitrate appears in plasma. With transdermal glyceryl trinitrate controlled-release systems, plasma concentrations of glyceryl trinitrate can be maintained over 24 hours, although with fluctuations and important intraindividual and interindividual variability. After administration of glyceryl trinitrate via different routes, glyceryl dinitrates and mononitrates are present in plasma. The pharmacokinetics of isosorbide dinitrate are somewhat easier to understand. The substance disappears less rapidly from the plasma than does glyceryl trinitrate. After oral administration, there is also a hepatic first-pass extraction; the plasma concentrations can be prolonged by administering slow-release products. Sublingual administration leads to higher plasma concentrations than oral administration. Isosorbide dinitrate is metabolized in the organism to isosorbide 5-mononitrate and isosorbide 2-mononitrate, which both have vasodilator activity: after administration of isosorbide dinitrate, the mononitrates, and mainly the 5-mononitrate, reach very high concentrations in plasma. Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>7873466</pmid><doi>10.1007/bf00877116</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0920-3206 |
ispartof | Cardiovascular drugs and therapy, 1994-10, Vol.8 (5), p.693-699 |
issn | 0920-3206 1573-7241 |
language | eng |
recordid | cdi_proquest_miscellaneous_77765742 |
source | Springer Nature - Connect here FIRST to enable access |
subjects | Angina Pectoris - drug therapy Antianginal agents. Coronary vasodilator agents Biological and medical sciences Cardiovascular system Delayed-Action Preparations Drug Administration Routes Half-Life Humans Isosorbide Dinitrate - administration & dosage Isosorbide Dinitrate - analogs & derivatives Isosorbide Dinitrate - blood Isosorbide Dinitrate - pharmacokinetics Isosorbide Dinitrate - therapeutic use Liver - metabolism Medical sciences Nitrates - administration & dosage Nitrates - blood Nitrates - pharmacokinetics Nitrates - therapeutic use Nitroglycerin - blood Nitroglycerin - pharmacokinetics Pharmacology. Drug treatments Structure-Activity Relationship Vasodilation - drug effects Vasodilator Agents - blood Vasodilator Agents - pharmacokinetics Vasodilator Agents - therapeutic use |
title | Clinical pharmacokinetics of nitrates |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A59%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20pharmacokinetics%20of%20nitrates&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=BOGAERT,%20M.%20G&rft.date=1994-10-01&rft.volume=8&rft.issue=5&rft.spage=693&rft.epage=699&rft.pages=693-699&rft.issn=0920-3206&rft.eissn=1573-7241&rft.coden=CDTHET&rft_id=info:doi/10.1007/bf00877116&rft_dat=%3Cproquest_cross%3E77765742%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c340t-da3d50861c6f47f371bc568f8b8c69bc325b7aea600af4bf4f21045c691e221b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77765742&rft_id=info:pmid/7873466&rfr_iscdi=true |